29 studies found for:
" July 16, 2008":" August 15, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Completed |
Lovastatin: Immunomodulatory Value Evaluation
|
||||
| 2 |
Completed
Has Results |
Safety and Efficacy Study of Switching From Epzicom to Truvada
|
||||
| 3 | Completed |
Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS
|
||||
| 4 | Recruiting |
Intervention for (Those) Recently Informed of Seropositive Status (IRISS)
|
||||
| 5 | Completed |
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy
|
||||
| 6 |
Completed
Has Results |
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
|
||||
| 7 | Active, not recruiting |
Study of Raltegravir Versus Nucleotide Reverse Transcriptase Inhibitors (NRTIs) as a Backbone in HIV-Infected Subjects Switched From a Stable Boosted Protease Inhibitor (PI) Regimen
|
||||
| 8 |
Completed
Has Results |
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
|
||||
| 9 | Active, not recruiting |
Bone Mineral Density Substudy - An Ancillary Study to MTN-003
|
||||
| 10 | Completed |
Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
|
||||
| 11 | Completed |
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
|
||||
| 12 | Completed |
Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families
|
||||
| 13 | Completed |
The Effect of Vitamin D and Calcium on Bone in Pediatric HIV
|
||||
| 14 | Enrolling by invitation |
Cerebrospinal Fluid (CSF) Raltegravir Substudy
|
||||
| 15 | Completed |
GSK706769/KALETRA Drug-drug Interaction Study
|
||||
| 16 | Recruiting |
Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART
|
||||
| 17 | Completed |
Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers
|
||||
| 18 | Completed |
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
|
||||
| 19 | Completed |
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
|
||||
| 20 | Withdrawn |
Maraviroc Compassionate Use
|
† Indicates status has not been verified in more than two years
